Tuesday, November 17, 2026Tue, Nov 17 Updated

Mergers, acquisitions and startup deals, and what they mean.

Isomorphic Labs Raises $5 Billion Series C to Reach Clinical Trials

Isomorphic Labs, the AI drug-discovery company spun out of DeepMind, raised $5 billion led by Greenoaks and Sequoia. Investors, plans and valuation.

Close-up of colorful test tubes with blue caps in a laboratory setting.
Photo: Polina Tankilevitch / Pexels

Isomorphic Labs, the AI drug-discovery company spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C round. The company plans to use the money to move its drug candidates into clinical trials, according to TechCrunch.

The round arrives only months after Isomorphic closed a $2.1 billion Series B in May. The company did not disclose its new valuation.

Who put money into the round

Greenoaks and Sequoia Capital co-led the Series C. Andreessen Horowitz joined as a new investor, and other investors also took part. Every existing backer also took part, including GV and Capital G (Alphabet’s venture arms), Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.

Bloomberg reported earlier this month that Isomorphic was seeking funding at a $50 billion valuation. The company has not confirmed that figure.

What Isomorphic does

Isomorphic builds what it calls a drug-design engine: a set of AI simulation models that explore different areas of chemistry to help design new medicines. Its work grows out of AlphaFold, the DeepMind system that predicts a protein’s 3D structure from its genetic sequence alone. Demis Hassabis and John Jumper, then a director at DeepMind, won the Nobel Prize in chemistry for AlphaFold.

The company said its program has produced “positive preclinical results” in oncology and immunology, meaning results from lab and animal work done before any testing in people. It has signed partnerships with Eli Lilly, Novartis and Johnson & Johnson.

What the money will pay for

Isomorphic said the new capital will go toward further development of its drug-design engine and toward expanding into more types of medicine. The main goal named in the announcement is taking its own drug candidates into clinical trials, the stage where treatments are tested in patients for the first time.

Why it matters

The Series C moves Isomorphic from a research platform that sells its work to drugmakers toward a company that wants to run its own trials. That shift is what the new money is meant to pay for. Shareholders in Alphabet have a direct interest, since two of its venture divisions, GV and Capital G, invested again in this round. For partners such as Eli Lilly, Novartis and Johnson & Johnson, the open question is whether the engine’s candidates hold up in people, something the company’s preclinical results cannot show on their own.

It is also the first fundraise since Hassabis, Isomorphic’s founder and CEO, stepped down as head of DeepMind to focus on drug discovery. He moved into a chairman role at DeepMind as part of that change.

What to watch

Isomorphic has not said when its first trial will start or which candidate will go first. The next disclosures to look for are a confirmed valuation and the first clinical trial filing for one of its oncology or immunology programs.

Source: TechCrunch